Results of the ECOG E3805 Study

FDA updates talazoparib and enzalutamide labeling, confirming survival benefits for HRR-mutated mCRPC, while excluding non-HRR patients.

Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.

A new platform comprehensively profiles CAR T-cells during manufacturing, revealing phenotypic shifts. This allows for shorter timelines, better outcomes, and personalized therapies.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Hyung Kim, MD, discussed the PROBE trial, a trial in progress, for patients with advanced kidney cancer.

The FDA approved intravesical mitomycin in non–muscle-invasive bladder cancer as an nonsurgical alternative to transurethral resection of bladder tumors.